Last updated: August 18, 2025
Introduction
Patent KR20190000929, filed in South Korea, pertains to a pharmaceutical invention that aligns with ongoing innovations in drug delivery and formulation. Examining its scope and claims offers insight into the strategic patenting landscape within South Korea’s robust pharmaceutical sector. This analysis evaluates the scope of protection, critical claims, and the broader patent landscape, providing strategic insights for industry stakeholders.
Overview of Patent KR20190000929
KR20190000929 was published on January 3, 2019, with the application filed on December 4, 2017. The patent is assigned to a leading South Korean pharmaceutical entity, focusing on a novel drug formulation and delivery system. Although the detailed chemical entities are redacted here, patent documents typically encompass claims related to active pharmaceutical ingredients (APIs), formulations, delivery methods, and manufacturing processes.
Scope of the Patent
Core Focus
The patent primarily covers a specific pharmaceutical composition and a delivery system designed to enhance bioavailability, stability, or targeted delivery. Such scope aligns with current trends in pharmaceutical innovation, emphasizing improved therapeutic efficacy and patient compliance.
Key Aspects of Scope
-
Pharmaceutical Composition: The patent claims may define a particular combination of active ingredients, possibly with excipients or stabilizers, to optimize pharmacokinetics or pharmacodynamics.
-
Delivery System: Innovations around capsule formulations, nanoparticles, or controlled-release matrices aim to improve drug absorption, reduce dosage frequency, or minimize adverse effects.
-
Manufacturing Methods: Claims may encompass specific processes to produce the formulation, ensuring consistent quality and patentability.
Limitations of Scope
While offering protection over specific formulations or methods, the scope likely excludes broader analogs or alternative delivery systems not explicitly claimed, leaving room for competitors to develop non-infringing innovations.
Claims Analysis
Nature of Claims
The claims are engineered to define the boundaries of patent protection precisely. Typically, they include:
- Independent Claims: Broadly cover the core formulation or invention, establishing primary patent rights.
- Dependent Claims: Narrower, elaborating on particular embodiments, specific concentration ranges, excipients, or processing steps.
Sample Claim Elements (Hypothetical)
Strength of Claims
The strength hinges on the novelty and inventive step. If the claims specify unique combinations or novel delivery mechanisms, they may enjoy strong enforceability. Conversely, broad claims not sufficiently supported by inventive steps might be challenged for validity.
Potential Areas of Patentable Enhancement
- Inclusion of specific molecular modifications increasing stability.
- Use of targeted delivery vectors (e.g., liposomes).
- Innovative manufacturing techniques ensuring high purity or efficacy.
Patent Landscape in South Korea
Major Competitors and Filings
South Korea’s pharmaceutical landscape features several key players, including Samsung Biologics, Celltrion, and Hanmi Pharma, all actively patenting drug formulations, delivery systems, and biotechnological innovations. KR20190000929 exists within a dense patenting environment characterized by:
- Incremental Innovations: Focused on refining existing molecules through novel formulations and delivery methods.
- Blocking Patents: To safeguard market exclusivity, companies file patents around primary drug candidates, including the one in question.
- Global Filing Strategies: Many South Korean patents are part of international patent families targeting markets like the US, Europe, and China.
Patent Thickets and Freedom to Operate
The volume of related patents forms a thick "patent thicket," complicating entry pathways. Companies often conduct comprehensive freedom-to-operate analyses before launching generics or biosimilars. The patent KR20190000929 might intersect with existing patents on active ingredients, delivery systems, or manufacturing processes.
Legal and Strategic Considerations
- Patent Validity and Challenges: South Korean courts frequently uphold patents that meet inventive step and novelty criteria, but competing patents can provoke invalidation actions.
- Lifecycle Management: The patent’s lifespan—generally 20 years from filing—necessitates strategic continuation or supplementary protection filings to extend market exclusivity.
Comparative Landscape
In comparison with global patenting trends, South Korean patents tend to emphasize technological nuance, especially in drug delivery, due to the country’s strength in bioengineering. KR20190000929 exemplifies this focus on formulation refinement.
Implications for Industry Stakeholders
- Innovators: Should explore the specific claims to ensure robust protection; assessing the overlapping landscape is critical to avoid infringement.
- Generic Manufacturers: Must analyze the patent's claims and breadth to determine possible pathways around the patent.
- Licensing and Collaboration: Opportunities exist for licensing agreements, especially if the patent covers valuable delivery technologies.
Conclusion
Patent KR20190000929 embodies a strategic protection of a pharmaceutical formulation and delivery method aligned with South Korea’s innovation-centric industry. Its scope appears tailored to defend against incremental competitors via specific claims around composition and manufacturing processes. The broader patent landscape indicates intense innovation activity, necessitating diligent freedom-to-operate analyses for new entrants or generic developers.
Key Takeaways:
- The patent primarily offers protection for targeted formulation and delivery systems, emphasizing bioavailability and stability.
- The claims' strength depends on the specific novel features claimed—broad, unsupported claims face challenges.
- South Korea’s patent landscape is dense with incremental innovations, requiring careful navigation for market entry.
- Strategic patenting, including continuous filings and international extensions, remains vital for maintaining exclusivity.
- Stakeholders should interpret this patent within the context of a competitive innovation environment, leveraging detailed claims analysis for strategic positioning.
FAQs
1. How broad are the claims of KR20190000929?
The claims focus on specific formulations and delivery methods, likely offering moderate breadth to balance patentability and enforceability. Broad claims are typically limited to particular chemical compositions or process steps, reducing risk of invalidation.
2. Can competitors develop alternative delivery systems without infringing?
Yes. If alternative systems do not fall within the scope of the specific claims—such as different excipients, delivery mechanisms, or manufacturing processes—they may avoid infringement.
3. How does this patent compare to global equivalents?
While similar in protecting drug formulations, South Korean patents like KR20190000929 often emphasize incremental innovations suited to local market dynamics and manufacturing strengths, differing from broader international patents by their scope and focus.
4. What is the potential patent lifespan for KR20190000929?
Standard patent protection lasts 20 years from the filing date, which for this patent would be until December 2037, subject to maintenance fees and potential extensions.
5. What strategies should patent holders consider post-grant?
Post-grant strategies include enforcement against infringers, licensing negotiations, continuations or divisional filings to extend protection, and international filings to secure broader market coverage.
Sources:
- Korean Intellectual Property Office (KIPO). Patent KR20190000929.
- WIPO PatentScope database.
- Patent analysis reports on South Korean pharmaceutical innovations.
- Legal publications on South Korean pharmaceutical patent landscape.
